Connor, Clark & Lunn Investment Management (CC&L)’s AnaptysBio ANAB Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.79M	Buy	158,562 +36,086	+29%	+$1.94M	0.02%	510
2025 Q4	$5.94M	Buy	+122,476	New	+$4.77M	0.02%	597
2023 Q1	–	Sell	-28,465	Closed	-$882K	–	1229
2022 Q4	$882K	Sell	28,465 -37,369	-57%	-$1.06M	0.01%	737
2022 Q3	$1.68M	Sell	65,834 -7,444	-10%	-$174K	0.01%	530
2022 Q2	$1.49M	Sell	73,278 -5,149	-7%	-$114K	0.01%	531
2022 Q1	$1.94M	Sell	78,427 -9,642	-11%	-$292K	0.01%	506
2021 Q4	$3.06M	Buy	88,069 +187	+0.2%	+$5.93K	0.01%	437
2021 Q3	$2.38M	Buy	87,882 +7,733	+10%	+$196K	0.01%	490
2021 Q2	$2.08M	Buy	80,149 +1,532	+2%	+$36.7K	0.01%	531
2021 Q1	$1.69M	Buy	78,617 +3,000	+4%	+$75.7K	0.01%	598
2020 Q4	$1.63M	Sell	75,617 -11,834	-14%	-$287K	0.01%	553
2020 Q3	$1.29M	Sell	87,451 -19,340	-18%	-$349K	0.01%	572
2020 Q2	$2.39M	Sell	106,791 -2,109	-2%	-$38.6K	0.02%	420
2020 Q1	$1.54M	Buy	108,900 +18,600	+21%	+$282K	0.01%	471
2019 Q4	$1.47M	Buy	+90,300	New	+$2.14M	0.01%	473